SCHEMBL30200421

SCHEMBL30200421

CC(=O)c1c(Br)cc2c(c1O)OCCO2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.41
HPGD P15428 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.38
KDM4E B2RXH2 5/20 0.37
ALDH1A1 P00352 3/20 0.36
ALOX15 P16050 2/20 0.36
HSD17B10 Q99714 2/20 0.36
PLK1 P53350 1/20 0.35
LARS1 Q9P2J5 2/20 0.35
NPC1 O15118 1/20 0.35
GAA P10253 1/20 0.35
RAB9A P51151 1/20 0.35
CYP1A2 P05177 1/20 0.34
CYP2C19 P33261 1/20 0.34
L3MBTL4 Q8NA19 1/20 0.34
POLB P06746 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15988843 1.00 NPSR1 (0.41) NPSR1HPGDMEN1KMT2ASMN1; SMN2
SCHEMBL30200300 0.80 PLK1 (0.42) NPSR1HPGDMEN1KMT2ASMN1; SMN2
SCHEMBL15968932 0.80 PLK1 (0.42) NPSR1HPGDMEN1KMT2ASMN1; SMN2
SCHEMBL19341311 0.79 KDM4E (0.41) NPSR1HPGDMEN1KMT2ASMN1; SMN2
SCHEMBL27253937 0.75 SMN1; SMN2 (0.46) NPSR1HPGDMEN1KMT2ASMN1; SMN2
SCHEMBL22208563 0.71 SMN1; SMN2 (0.45) NPSR1HPGDMEN1KMT2ASMN1; SMN2
SCHEMBL31697147 0.71 SMN1; SMN2 (0.45) NPSR1HPGDMEN1KMT2ASMN1; SMN2
SCHEMBL9386246 0.70 SMN1; SMN2 (0.47) NPSR1HPGDMEN1KMT2ASMN1; SMN2
SCHEMBL7351377 0.69 KDM4E (0.38) NPSR1MEN1KMT2AKDM4EALDH1A1
SCHEMBL15324691 0.69 HPGD (0.45) NPSR1HPGDMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11673885-B2 γ-diketones as Wnt/β-catenin signaling pathway activators BIOSPLICE THERAPEUTICS, INC. (US) 2023-06-13 US disclosed
US-20230053726-A1 GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2023-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230053726-A1 GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS GSK3A, GSK3B, WNT1 NPSR1 3620/4885HPGD 1118/4885MEN1 3089/4885
US-11673885-B2 γ-diketones as Wnt/β-catenin signaling pathway activators GSK3A, GSK3B, WNT1 NPSR1 3592/4885HPGD 1166/4885MEN1 3158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.